MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Organovo Holdings Operating Income 2011-2026 | ONVO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.6 M | -15.1 M | -17.7 M | -16.8 M | -21.5 M | -27.3 M | -35.3 M | -38.6 M | -38.6 M | -30.3 M | -20.6 M | - | -9.32 M | -2.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.3 M | -38.6 M | -22 M |
Quarterly Operating Income Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.75 M | -2.64 M | -2.92 M | - | -3.47 M | -2.61 M | -3.39 M | - | -3.68 M | -4.12 M | -4.2 M | - | -3.36 M | -3.35 M | -3.24 M | - | -3.5 M | -9.57 M | -6.07 M | - | -2.49 M | -2.49 M | -8.95 M | -2.79 M | -5.23 M | -5.23 M | -6.83 M | -6.52 M | -6.53 M | -6.53 M | -6.01 M | - | -7.91 M | -9.58 M | -10.2 M | - | -9.63 M | -27.9 M | -18.3 M | - | -10.5 M | -30.2 M | -19.7 M | - | -6.96 M | -22.3 M | -15.4 M | - | -4.63 M | -14 M | -9.34 M | -4.02 M | -2.92 M | -7.99 M | -5.07 M | -1.33 M | - | -622 K | -474 K | -492 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -474 K | -30.2 M | -7.3 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
1.35 B | $ 110.24 | -2.86 % | $ 33.5 B |  USA |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Waters Corporation
WAT
|
271 M | $ 289.16 | -3.79 % | $ 17.2 B | USA |
 |
Exagen
XGN
|
-14.1 M | $ 2.68 | -3.94 % | $ 57.8 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.36 | -11.57 % | $ 176 M |  China |
 |
Sotera Health Company
SHC
|
248 M | $ 13.13 | -3.03 % | $ 3.73 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 26.78 | -1.33 % | $ 20 B |  Niderland |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 102.08 | -0.97 % | $ 8.42 B |  Irlanda |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
BioNano Genomics
BNGO
|
-33.3 M | $ 1.16 | 0.87 % | $ 6.32 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
912 M | $ 62.25 | -5.81 % | $ 24.3 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 23.53 | -4.74 % | $ 654 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 159.16 | -3.62 % | $ 7.89 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 195.51 | -1.33 % | $ 21.7 B | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
PerkinElmer
PKI
|
357 M | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
8.11 M | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 8.7 | -4.92 % | $ 1.89 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 264.2 | -1.56 % | $ 22 B | USA |
 |
Psychemedics Corporation
PMD
|
-2.92 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
-7.62 M | $ 25.97 | -4.52 % | $ 33.7 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 16.78 | -3.95 % | $ 894 M | USA |
 |
Quotient Limited
QTNT
|
-82.7 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Syneos Health
SYNH
|
389 M | - | - | $ 4.46 B | USA |
 |
Renalytix AI plc
RNLX
|
-29.6 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
VolitionRx Limited
VNRX
|
-27 M | $ 0.2 | 1.87 % | $ 19.2 M |  Singapore |
 |
Bioventus
BVS
|
54 M | $ 8.94 | -3.46 % | $ 596 M | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Meridian Bioscience
VIVO
|
54.4 M | - | - | $ 1.49 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 181.52 | -3.27 % | $ 129 B | USA |